These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 923986)

  • 21. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
    Braun DP; Mokyr MB; Dray S
    Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cadmium modification of the response in Balb/c mice to MOPC-104E tumor.
    Gray I; Arrieh M; Balter NJ
    Arch Environ Health; 1982; 37(6):342-5. PubMed ID: 7181534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation.
    Mokyr MB; Braun DP; Dray S
    Cancer Res; 1979 Mar; 39(3):785-92. PubMed ID: 427766
    [No Abstract]   [Full Text] [Related]  

  • 24. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of an IgM plasmacytoma (TEPC-183) on the primary immune response of BALB/c mice.
    Havas HF; Schiffman G
    Immunology; 1978 Jan; 34(1):1-8. PubMed ID: 23993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type C virus and immunoglobulin A production by murine myeloma MOPC-315: two independent activities.
    Gazit A; Yaniv A; Halperin D; Ben-Efraim S
    Infect Immun; 1979 Aug; 25(2):569-73. PubMed ID: 226480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re-expression of nonglycosylated surface IgA in trypsin-treated MOPC 315 plasmacytoma cells.
    Hickman S; Wong-Yip YP
    J Immunol; 1979 Jul; 123(1):389-95. PubMed ID: 448154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antigenic markers of variable region of mouse myeloma MOPC 21 light chain].
    Vengerova TI; Petrosian MN; Bogacheva GT; Rokhlin OV
    Mol Biol (Mosk); 1979; 13(6):1303-11. PubMed ID: 94936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation and properties of an antiplasma cell serum directed against a defined plasmacytoma cell population.
    Proctor ML; Herscowitz HB
    J Immunol; 1975 Dec; 115(6):1642-9. PubMed ID: 1184969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alteration of cell-surface antigenicity of the mouse plasmacytoma. I. Immunologic characterization of surface antigens masked during successive transplantations.
    Ono S; Natsu-ume S; Migita S
    J Natl Cancer Inst; 1975 Sep; 55(3):569-77. PubMed ID: 51090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization.
    Mokyr MB; Hengst JC; Przepiorka D; Dray S
    Cancer Res; 1979 Oct; 39(10):3928-34. PubMed ID: 157800
    [No Abstract]   [Full Text] [Related]  

  • 32. Idiotype-specific suppression of MOPC-315 IgA secretion in vivo: reversible blockade of secretory myeloma cells by soluble mediators.
    Rohrer JW; Odermatt B; Lynch RG
    J Immunol; 1978 Nov; 121(5):1799-807. PubMed ID: 712066
    [No Abstract]   [Full Text] [Related]  

  • 33. Myeloma cell immunoglobulin expression during in vivo growth in diffusion chambers: evidence for repetitive cycles of differentiation.
    Rohrer JW; Vasa K; Lynch RG
    J Immunol; 1977 Sep; 119(3):861-6. PubMed ID: 330758
    [No Abstract]   [Full Text] [Related]  

  • 34. Tumor-associated antigen (TAA) and anti-TAA antibodies in the serum of BALB-c mice with plasmacytomas.
    Kolb JP; Poupon MF; Lespinats G
    J Natl Cancer Inst; 1974 Mar; 52(3):723-7. PubMed ID: 4826560
    [No Abstract]   [Full Text] [Related]  

  • 35. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.
    Sirisinha S; Eisen HN
    Proc Natl Acad Sci U S A; 1971 Dec; 68(12):3130-5. PubMed ID: 4108872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alteration of immunoglobulin phenotype in cell culture-adapted lines of two mouse plasmacytomas.
    Hausman SJ; Bosma MJ
    J Exp Med; 1975 Oct; 142(4):998-1010. PubMed ID: 51902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Murine plasma cells secreting more than one class of immunoglobulin heavy chain. II. SAMM 368--a plasmacytoma secreting IgG2b-kappa and IgA-kappa immunoglobulins which do not share idiotypic determinants.
    Morse HC; Neiders ME; Lieberman R; Lawton AR; Asofsky R
    J Immunol; 1977 May; 118(5):1682-9. PubMed ID: 67144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
    [No Abstract]   [Full Text] [Related]  

  • 39. A new T cell neoplasm expressing surface anti-DNP activity, developed from the thymus of mice bearing MOPC-315 plasma cell tumors.
    Lahat N; Moroz C
    Adv Exp Med Biol; 1976; 66():477-81. PubMed ID: 1083649
    [No Abstract]   [Full Text] [Related]  

  • 40. T cell lymphoma expressing immunoglobulin with DNP-binding activity--a possible model for T cell receptor.
    Moroz C; Lahat N
    Mol Immunol; 1980 Jul; 17(7):905-12. PubMed ID: 7219416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.